Indication: Antiinflammatory and antimicrobial compounds and compositions
US Patent No: US 4,837,228 A
Filing Date: Jun 6, 1989
The use of cannabichromene (CBC) and its homologues and isomers to induce hypothermia, reduce inflammation in mammals, and as antimicrobial agents is disclosed. Preferably, a compound selected from cannabichromene, its homologues and isomers, is administered as a novel composition, in combination with a pharmaceutically acceptable diluent carrier.
Indication: A method of treating glaucoma
U.S. Patent No: US 4,189,491 A
Filing Date: Feb 19, 1980
Significant success in alleviating the symptoms of glaucoma is achieved by orally administering to a glaucoma sufferer a therapeutically effective, but sub-psychotropic dose of tetrahydrocannabinol (THC), which is the most active ingredient in marijuana. The most significant results are achieved when this form of treatment is combined with conventional types of anti-glaucoma treatment, although in a limited number of cases, THC therapy alone proved successful. Also disclosed is a dosage unit form for THC comprising a suitable dose of THC in combination with an innocuous diluent such as fructose.
Indication: Anandamides useful for the treatment of intraocular hypertension, ophthalmic compositions containing the same and methods of use of the same
U.S. Patent No: US 5,631,297 A
Filing Date: May 20, 1997
Anandamides useful for the treatment of intraocular hypertension, as well as ophthalmic compositions comprising the same and a cyclodextrin, and methods of use of these compounds to treat intraocular hypertension.
Transcutaneous application of marijuana
Indication: Pain, inflammation and arthritis
U.S. Patent No: US 6,132,762 A
A transcutaneous therapeutic formulation comprising marijuana and a carrier for the treatment of pain, inflammation, arthritis and related disorders in humans and animals.
Cannabidiol and inflammatory diseases
Use of cannabinoids as anti-inflammatory agents
US Patent No: US 6,410,588 B1
The application relates to the identification that cannabinoids, such as cannabidiol can be used to treat inflammatory diseases. Cannabinoids for use in treating inflammatory diseases, methods of treating inflammatory diseases and cannabinoids in combination with pharmaceutically acceptable carriers are claimed.
Treatment for coughs
Treatment for cough
US Patent No: US 6,974,568 B2
The invention discloses the existence of cannabinoid receptors in the airways, which are functionally linked to inhibition of cough. Locally acting cannabinoid agents can be administered to the airways of a subject to ameliorate cough, without causing the psychoactive effects characteristic of systemically administered cannabinoids. In addition, locally or systemically administered cannabinoid inactivation inhibitors can also be used to ameliorate cough. The present invention also defines conditions under which cannabinoid agents can be administered to produce anti-tussive effects devoid of bronchial constriction.
Inflammatory and autoimmune diseases
Strokes, Alzheimer's and Parkinson's
Cannabinoids as antioxidants and neuroprotectants
US Patent No: US 6,630,507 B1
Cannabinoids have been found to have antioxidant properties, unrelated to NMDA receptor antagonism. This new found property makes cannabinoids useful in the treatment and prophylaxis of wide variety of oxidation associated diseases, such as ischemic, age-related, inflammatory and autoimmune diseases. The cannabinoids are found to have particular application as neuroprotectants, for example in limiting neurological damage following ischemic insults, such as stroke and trauma, or in the treatment of neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease and HIV dementia. Nonpsychoactive cannabinoids, such as cannabidoil, are particularly advantageous to use because they avoid toxicity that is encountered with psychoactive cannabinoids at high doses useful in the method of the present invention. A particular disclosed class of cannabinoids useful as neuroprotective antioxidants is formula (I) wherein the R group is independently selected from the group consisting of H, CH3, and COCH3.
Novel polycyclic cannabinoid analogs
Dibenzo[b,d]pyran-6-ones used for providing a physiological effect to treat pain, pain associated with cancer, chemotherapy, neuropathy, Multiple Sclerosis, Parkinson's Disease, Huntington's Chorea, Alzheimer's Disease, Amyotrophic Lateral Sclerosis, and inflammation; antinociceptive agents
US Patent No: US 7741365 B2
Novel polycyclic cannabinoid analogs are presented which have preferentially high affinities for the cannabinoid CB2 receptor sites.
Prostate cancer and prostatitis
aqueous extract of finely chopped dried selenium- and zinc-enhanced cannabis (Cannabis indicaxCannabis ruderalis), chopped shiitake mushrooms (Lentinula edodes), and chopped maitake mushrooms (Grifola frondosa) packaged in a cellulose capsule for oral adminstration to treat prostatitis, prostate cancer
US Patent No: US 7,597,910 B2
Compositions and methods are described for the treatment of prostatitis, benign prostatic hypertrophy, and prostate cancer. The compositions contain either aqueous extracts or dried mixtures of selenium- and zinc-enriched cannabis plant material, shiitake mushrooms, and maitake mushrooms. The compositions are effective in treating prostate disorders by alleviating pain and voiding symptoms, decreasing inflammation and prostate size, reducing cellular proliferation in prostate tissue, and/or reducing PSA levels to within the normal range of 0-4.
Detecting traces of cannabinoids
Oral detection test for cannabinoid use
US Patent No: US 7,977,107 B2
A method for confirming the active intake of marijuana and its active component Δ9-tetrahydrocannabinol (“Δ9-THC”) by detecting the amount of 11-nor-Δ9-THC carboxylic acid (“THCA”) in oral fluid at the picogram per milliliter (pg/ml) level using chromatography/mass spectrometry/mass spectrometry (“GC/MS/MS”).
Diabetes and insulitis
Treating or preventing diabetes with cannabidiol
US Patent No: US 8,071,641 B2
Use of a cannabidiol for the manufacture of a medicament identified for the treatment or prevention of diabetes and/or insulitis.
Cannabidiol and autoimmune hepatitis
Use of cannabidiol in the treatment of autoimmune hepatitis
US Patent No: US 8,242,178 B2
Methods of treating autoimmune hepatitis are provided. The methods include injecting cannabidiol into the subject, where the cannabidiol is synthetic cannabidiol or natural cannabidiol isolated from other natural cannabinoids.
Nausea, vomiting and motion sickness
cannabis extract; containing a pharmaceutically acceptable amount of CBD and/or CBDA and/or the propyl variants CBDV and/or CBDVA
US Patent No: US 8,034,843 B2
Cannabinoids, in particular CBD and CBDA and their acid derivatives are provided for use as an active pharmaceutical substance in the treatment of nausea, vomiting, emesis, motion sickness. In particular extracts of cannabis plants are presented which are rich in these substances and suitable for pharmaceutical use.
Therapeutic uses of cannabigerol
US Patent No: US 20100292345 A1
The present invention relates to the use of the cannabinoid cannabigerol (CBG) in the manufacture of medicaments for use in the treatment of diseases and conditions benefiting from concurrent agonism of the CBi and the CB2 cannabinoid receptors. Such diseases or conditions to be treated are taken from the group: pain, neurodegenerative disease, ischemic disease, brain injury or damage, acquired brain injury, age related inflammatory or autoimmune disease, cachexia, nausea and vomiting, glaucoma, movement disorders, rheumatoid arthritis, asthma, allergy, psoriasis, Crohn's disease, systemic lupus erythematosus, diabetes, cancer, osteoporosis, renal ischemia and nephritis.
Multiple sclerosis and MS relapse
inter alia, treating and/or preventing symptoms; Spasticity
US Patent No: US 20080181942 A1
Methods are provided for, inter alia, treating and/or preventing symptoms associated with multiple sclerosis and MS relapse.
Chronic Obstructive Pulmonary Disease
Pharmaceutical Compositons for the Treatment of Chronic Obstructive Pulmonary Disease
US Patent No: US 20090197941 A1
The invention relates to the use of a combination of cannabinoids for the treatment of Chronic Obstructive Pulmonary Disease (COPD). Preferably the combination of cannabinoids are cannabidiol (CBD) and delta-9-tetrahydrocannabinol (THC). More preferably the cannabinoids are in a predefined ratio by weight of approximately 1:1 of CBD to THC.
Treating cell proliferation and cancers
Methods and compositions for treating cancer
US Patent No: US 20100204312 A1
This disclosure provides compositions and method useful for treating cell proliferative disorders including cancer. The disclosure provides cannabidiol derivatives and compositions thereof either alone or in combination with THC or a derivative thereof.
Inhibition of tumour cell migration
Administering cannabidiol produced from a given cannabis chemovar and in the form of a botanical drug substance; modulators motility of glioma cell motility; uneffected by involvement of cannabinoid receptor antagonists; antitumor, anticarcinogenic, antiproliferative and antimetastsis agents.
US Patent No: 20080262099 A1
The invention relates to the use of a cannabis plant extract or a cannabinoid as a pharmaceutically active agent in the inhibition of tumour cell migration.
Gastrointestinal inflammatory and cancers
Composition containing non-psychotropic cannabinoids for the treatment of inflammatory diseases
US Patent No: US 20100222437 A1
The invention relates to a composition comprising cannabidiol and Denbinobin and its use in medicine, for example, for the prevention and treatment of gastrointestinal inflammatory diseases and for the prevention and treatment of gastrointestinal cancers.
This Research and Resources page is sponsored by the Ohio Rights Group Education Fund.
Please support our charitable and educational work by making a generous tax deductible donation.